Getinet Ayalew, MD
Hematology & Oncology · Bridgeton, MONPI 1326235797
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 40 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 11.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $614 and has fallen 93.9% since, to $37 in 2025. That places this record below the midpoint for hematology & oncology clinicians in MO, where the typical reported total is $1,571.
Across 40 payments — averaging $18.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$88
- Bristol Myers Squibb$69
- Novartis$59
- Pharmacyclics LLC, An Abbvie Company$56
- Regeneron Healthcare Solutions, Inc.$56
- Beigene USA, Inc.$54
- plus $360 from 15 others
Across 3 payments — averaging $31,517 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$95K
What the payments were for
- Food & beverage$72998%
- Education$122%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead(2 entities) | 4 | $88 |
| Bristol Myers Squibb | 5 | $69 |
| Novartis | 3 | $59 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $56 |
| Regeneron Healthcare Solutions, Inc. | 3 | $56 |
| Beigene USA, Inc. | 3 | $54 |
| Astellas Pharma US Inc | 2 | $47 |
| Seagen Inc. | 2 | $41 |
| Merck | 2 | $38 |
| Johnson & Johnson(2 entities) | 2 | $36 |
| Mirati Therapeutics, Inc. | 2 | $29 |
| Stemline Therapeutics Inc. | 1 | $25 |
| Sanofi | 1 | $21 |
| Lilly USA, LLC | 1 | $19 |
| Pfizer | 1 | $18 |
| AVEO Pharmaceuticals, Inc. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Array Biopharma Inc | 1 | $14 |
| Sobi, Inc | 1 | $14 |
| AstraZeneca | 1 | $14 |
| EMD Serono, Inc. | 1 | $14 |
How this compares
$741 in reported general payments places this provider in the 35th percentile of 211 hematology & oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 36 | $543,670 |
| FruzaqlaFruquintinib | 18 | $434,350 |
| ImbruvicaIbrutinib | 25 | $413,570 |
| RevlimidLenalidomide | 18 | $403,633 |
| VerzenioAbemaciclib | 22 | $333,846 |
| CalquenceAcalabrutinib Maleate | 21 | $324,360 |
| Lenalidomide | 22 | $317,082 |
| EliquisApixaban | 42 | $32,914 |
| Abiraterone Acetate | 58 | $10,774 |
| Ondansetron Hcl | 52 | $4,297 |
| Anastrozole | 249 | $3,408 |
| Tamoxifen Citrate | 120 | $2,675 |
| Fentanyl | 26 | $2,114 |
| Dexamethasone | 83 | $1,533 |
| Hydroxyurea | 54 | $1,148 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $54 | $543,67036 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $56 | $413,57025 claims |
| Bristol Myers SquibbRevlimid | $69 | $403,63318 claims |
| Lilly USA, LLCVerzenio, Olanzapine | $19 | $333,97339 claims |
| AstraZenecaCalquence | $14 | $324,36021 claims |
| PfizerEliquis | $18 | $32,91442 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 211 hematology & oncology providers in Missouri.
Other hematology & oncology in Bridgeton
- Giancarlo PillotBridgeton$14K
- David SchlossmanColumbia$1.2M
- Mark FeslerSaint Louis$870K
- Kelly PendergrassLees Summit$189K
- Jonathan MizrahiSaint Louis$188K
- Shahzad RazaKansas City$123K
- Stephanie GraffKansas City$105K
- Muhammad MirzaWashington$65K
- Yifan TuSt. Louis$64K
- Whitney HensingKansas City$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.